(Business) – On Monday, gene and cell therapy firm Oxford Biomedica signed a new manufacturing agreement for scaling up the production of AstraZeneca’s potential COVID-19 vaccine to cater to the vaccine’s demand in the UK and Europe.
Last week, Oxford Biomedica appointed a new chair looking to get a bigger role in vaccine manufacturing. The five-year partnership with the UK’s Vaccines Manufacturing and Innovation Centre (VMIC) will aid help it make other viral vector vaccines.
(Photo syndicated via Reuters)
This story has been edited by BH staff and is published from a syndicated field.